NCT02576119 - A Study to Determine the Effect of Multiple Doses of BMS-955176 on the Electrocardiograph of Healthy Subjects | Biotech Hunter

Enrollment

315

Participants

Timeline

Start Date

October 19, 2015

Primary Completion Date

February 26, 2016

Study Completion Date

October 14, 2016

Conditions

Infection, Human Immunodeficiency Virus

Interventions

DRUG

BMS-955176, Placebo (Part 1)

The BMS-955176 dose in sentinel Cohort 1 will be 240 mg orally. The BMS-955176 dose in sentinel Cohort 2 will be determined based on the results of data from sentinel Cohort 1.

DRUG

BMS-955176, Moxifloxacin, Placebo (Part 2)

Subjects will be randomized to 1 of 12 sequences. Each sequence includes combination of different regimens (combination of BMS-955176, placebo and Moxifloxacin).

Trial Locations (1)

78744

GSK Investigational Site, Austin